Newsletter

12/29/2023 – Our Best Wishes for the New Year 2024 | Reig Jofre

12/20/2023 – Appointment of the new Chief Financial Officer (CFO)

11/02/2023 – Reig Jofre reaches the milestone of 15 million vials of its intravenous anesthetic sold in Japan

10/30/2023 – Reig Jofre submits press release on the results of the third quarter of 2023

09/26/2023 – REIG JOFRE appointed Alex Sanfeliu as the new Global Head of Pharmaceutical Technologies business unit

07/27/2023 – Reig Jofre submits press release on the results of the second quarter of 2023

07/03/2023 – Extension the liquidity contract

06/30/2023 – Reig Jofre and Zendal appointed by the EU to ensure vaccine production capacity in Europe in case of future health emergencies

06/14/2023 – Reig Jofre informs on the start date of the trading of new shares of the Scrip Dividend

05/31/2023 – Ending of the process for the bonus-shares capital increase

05/04/2023 – Reig Jofre submits the schedule of the scrip dividend | Execution of the Scrip Dividend

04/28/2023 – Reig Jofre informs on the Scrip Dividend Conditions

04/11/2023 – 2023 General Shareholders’ Meeting Resolutions | Transactions within the liquidity contract

03/01/2023 – Reig Jofre convenes its 2023 General Shareholders Meeting

02/28/2023 – Reig Jofre submits results note on fourth quarter of 2022

12/13/2022 – Reig Jofre has successfully completed the co-development of TRIFERTY-ATM®, a food supplement that contributes to male fertility

11/02/2022 – REIG JOFRE submits press release on the global license agreement reached by Syna Therapeutics

10/28/2022 – Reig Jofre submits results note on third quarter of 2022

10/26/2022 – The Company announces the release date of its Q3 2022 results

09/07/2022 – FORTÉ PHARMA, REIG JOFRE’s brand of food supplements launches its E-commerce in China

07/26/2022 – Reig Jofre submits results note on second quarter of 2022

07/25/2022 – Reig Jofre informs on the start date of the trading of the new shares within its scrip dividend

07/12/2022 – Reig Jofre informs on the bonus-shares capital increase and the new shares to be issued for its scrip dividend

06/14/2022 – Execution of the scrip dividend

06/09/2022 – Reig Jofre informs on the Scrip Dividend Conditions

05/23/2022 – Reig Jofre launches Regenail® topical solution for structural nail alterations

04/29/2022 – Resolutions on 2022 General Shareholders´ Meeting

02/28/2022 – Reig Jofre submits results note on fourth quarter of 2021

11/15/2021 – Bioglan and Stada partner to increase capacity to meet rising demand for Parkinson´s treatment

10/29/2021 – Reig Jofre submits results note on third quarter of 2021

07/29/2021 – Reig Jofre submits results note on second quarter of 2021

07/22/2021 – Reig Jofre acquires 100% of REIG JOFRE UK LTD and consolidates its presence in the United Kingdom

07/21/2021 – Start of the trading of the new shares within its scrip dividend

07/06/2021 – Completion of liquidity contract | Increase in the bonus-share capital | Start of the second temporary share buyback program

06/09/2021 – Execution of the scrip dividend and conditions

05/11/2021 – Changes in the Board of Directors

04/29/2021 – Reig Jofre submits results note on the first quarter of 2021

04/26/2021 – Date change for release of the 1Q 2021 result note

04/20/2021 – Reig Jofre opens a subsidiary in Poland

03/26/2021 – Reig Jofre convenes its 2021 General Shareholders´ Meeting

02/26/2021 – Reig Jofre submits results note on the fourth quarter of 2020

12/15/2020 – Reig Jofre announces technology transfer of the large scale manufacturing in Spain for a Covid-19 vaccine candidate

11/13/2020 – Reig Jofre submits results note on the third quarter of 2020

10/23/2020 – Reig Jofre informs on the start date of the trading of the new shares within its scrip dividend

10/09/2020 – Distribution of a dividend in the form of scrip dividend

09/15/2020 – Execution of the scrip dividend

09/10/2020 – Conditions of the scrip dividend

07/23/2020 – Reig Jofre releases first half 2020 results note

07/16/2020 – Reig Jofre contributes its know-how in the development of biological vaccines to the innovative consortium of Vaxdyn

06/18/2020 – Reschedule of 1H 2020 results

06/17/2020 – Reig Jofre convenes its 2020 General Shareholders´ Meeting

05/13/2020 – Reig Jofre cierra el primer trimestre de 2020 con un crecimiento del 26% en ventas